SI3424930T1 - Kristal spojine z učinkovitostjo zaviranja JAK - Google Patents

Kristal spojine z učinkovitostjo zaviranja JAK

Info

Publication number
SI3424930T1
SI3424930T1 SI201730521T SI201730521T SI3424930T1 SI 3424930 T1 SI3424930 T1 SI 3424930T1 SI 201730521 T SI201730521 T SI 201730521T SI 201730521 T SI201730521 T SI 201730521T SI 3424930 T1 SI3424930 T1 SI 3424930T1
Authority
SI
Slovenia
Prior art keywords
jak
crystal
compound
inhibiting activity
inhibiting
Prior art date
Application number
SI201730521T
Other languages
English (en)
Inventor
Fumi Higuchi
Original Assignee
Nippon Shinyaku Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co., Ltd. filed Critical Nippon Shinyaku Co., Ltd.
Publication of SI3424930T1 publication Critical patent/SI3424930T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SI201730521T 2016-03-01 2017-02-28 Kristal spojine z učinkovitostjo zaviranja JAK SI3424930T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016039315 2016-03-01
EP17759943.8A EP3424930B1 (en) 2016-03-01 2017-02-28 Crystal of compound having jak-inhibiting activity
PCT/JP2017/007594 WO2017150477A1 (ja) 2016-03-01 2017-02-28 Jak阻害作用を有する化合物の結晶

Publications (1)

Publication Number Publication Date
SI3424930T1 true SI3424930T1 (sl) 2021-01-29

Family

ID=59743962

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201730521T SI3424930T1 (sl) 2016-03-01 2017-02-28 Kristal spojine z učinkovitostjo zaviranja JAK

Country Status (21)

Country Link
US (2) US10822350B2 (sl)
EP (1) EP3424930B1 (sl)
JP (1) JP6791239B2 (sl)
KR (1) KR102653231B1 (sl)
CN (1) CN108699082B (sl)
BR (1) BR112018016523B1 (sl)
CA (2) CA3206830A1 (sl)
CY (1) CY1123607T1 (sl)
DK (1) DK3424930T3 (sl)
ES (1) ES2844978T3 (sl)
HR (1) HRP20210062T1 (sl)
HU (1) HUE051615T2 (sl)
LT (1) LT3424930T (sl)
MX (1) MX2018010334A (sl)
PL (1) PL3424930T3 (sl)
PT (1) PT3424930T (sl)
RS (1) RS61238B1 (sl)
RU (1) RU2705721C1 (sl)
SI (1) SI3424930T1 (sl)
TW (1) TWI712604B (sl)
WO (1) WO2017150477A1 (sl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI712604B (zh) * 2016-03-01 2020-12-11 日商日本新藥股份有限公司 具jak抑制作用之化合物之結晶
CA3192219A1 (en) * 2020-09-14 2022-03-17 Heiko HABERMULLER N-heterocyclic compounds used as nitrification inhibitor

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3600390A1 (de) 1986-01-09 1987-07-16 Hoechst Ag Diarylalkyl-substituierte alkylamine, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende arzneimittel
BRPI0506817A (pt) 2004-01-12 2007-05-29 Cytopia Res Pty Ltd inibidores seletivos de quinase
KR20080063809A (ko) * 2005-09-30 2008-07-07 버텍스 파마슈티칼스 인코포레이티드 야누스 키나아제의 억제제로서 유용한 데아자퓨린
EP2537849A3 (en) 2006-01-17 2013-04-03 Vertex Pharmaceuticals, Inc. Azaindoles useful as inhibitors of janus kinases
ES2602577T3 (es) 2008-03-11 2017-02-21 Incyte Holdings Corporation Derivados de azetidina y ciclobutano como inhibidores de JAK
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010070060A1 (en) * 2008-12-19 2010-06-24 Nerviano Medical Sciences S.R.L. Bicyclic pyrazoles as protein kinase inhibitors
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
ES2461967T3 (es) 2009-12-18 2014-05-21 Pfizer Inc. Compuestos de pirrolo[2,3-d]pirimidina
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
JP2011136925A (ja) 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
KR20140015162A (ko) 2010-01-12 2014-02-06 에프. 호프만-라 로슈 아게 트라이사이클릭 헤테로사이클릭 화합물, 조성물 및 이의 사용 방법
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
WO2012022045A1 (en) 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
WO2012037132A1 (en) 2010-09-14 2012-03-22 Exelixis, Inc. Phtalazine derivatives as jak1 inhibitors
WO2012054364A2 (en) 2010-10-22 2012-04-26 Merck Sharp & Dohme Corp. Bicyclic diamines as janus kinase inhibitors
WO2012085176A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
WO2013025628A1 (en) * 2011-08-15 2013-02-21 Ligand Pharmaceuticals Incorporated Janus kinase inhibitor compounds and methods
TWI679205B (zh) * 2014-09-02 2019-12-11 日商日本新藥股份有限公司 吡唑并噻唑化合物及醫藥
TWI712604B (zh) * 2016-03-01 2020-12-11 日商日本新藥股份有限公司 具jak抑制作用之化合物之結晶

Also Published As

Publication number Publication date
KR102653231B1 (ko) 2024-04-01
WO2017150477A1 (ja) 2017-09-08
EP3424930B1 (en) 2020-11-04
US20190048023A1 (en) 2019-02-14
TWI712604B (zh) 2020-12-11
JPWO2017150477A1 (ja) 2018-12-27
EP3424930A4 (en) 2019-07-10
PL3424930T3 (pl) 2021-05-04
ES2844978T3 (es) 2021-07-23
LT3424930T (lt) 2021-01-11
HRP20210062T1 (hr) 2021-03-05
TW201731855A (zh) 2017-09-16
CA3015464C (en) 2024-04-23
BR112018016523B1 (pt) 2024-02-06
RU2705721C1 (ru) 2019-11-11
CN108699082B (zh) 2021-04-09
US10822350B2 (en) 2020-11-03
CY1123607T1 (el) 2022-03-24
EP3424930A1 (en) 2019-01-09
BR112018016523A2 (pt) 2018-12-26
MX2018010334A (es) 2018-11-09
DK3424930T3 (da) 2021-01-11
PT3424930T (pt) 2020-12-04
HUE051615T2 (hu) 2021-03-01
RS61238B1 (sr) 2021-01-29
US20210017191A1 (en) 2021-01-21
JP6791239B2 (ja) 2020-11-25
KR20180116341A (ko) 2018-10-24
CN108699082A (zh) 2018-10-23
CA3206830A1 (en) 2017-09-08
US11377453B2 (en) 2022-07-05
CA3015464A1 (en) 2017-09-08

Similar Documents

Publication Publication Date Title
IL283267A (en) Inhibitors of menin–mll interaction
IL259560A (en) Inhibitors of the menin-mll interaction
HK1245266A1 (zh) 作為usp30抑制劑的1-氰基吡咯烷化合物
PL3512850T3 (pl) Inhibitory interakcji menina-mll
EP3268004A4 (en) Pyrrolopyridazine inhibitors of irak4 activity
EP3240412A4 (en) Use of picolinamide compounds with fungicidal activity
EP3240420A4 (en) Use of picolinamide compounds with fungicidal activity
EP3268006A4 (en) Pyrrolotriazine inhibitors of irak4 activity
HK1245770A1 (zh) 尿嘧啶化合物的新型結晶
IL273463A (en) Crystalline forms of immunomodulators
SG11201708793SA (en) Crystals of azabicyclic compound
SI3380554T1 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
HK1244274A1 (zh) C21h22ci2n4o2的晶型
IL262674A (en) crystals
IL253479A0 (en) Crystalline forms of efinconazole
PT3424930T (pt) Cristal de um composto com atividade inibidora de jak
EP3212611A4 (en) Crystal forms of verapamil hydrochloride
PT3395819T (pt) Forma cristalina de derivado de aminopirano substituído
ZA201901155B (en) Salt and crystal of diaza-benzofluorane compound
HK1247921A1 (zh) 哌嗪化合物的新晶體
EP3446689A4 (en) USE OF ISOTHIOCYANATE COMPOUNDS